HBIO
Harvard Bioscience Inc
$6.35
+0.20 (+3.25%)
At close · Jul 6
Market Cap
$29.00M
Shares
4,510,182
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.35
Open$6.07
Day$6.07–6.40
52W$3.80–9.40
Avg vol 30d20K
Short int89K · 2.0% float · 3.4d
Short vol44%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+10% above
+
Price vs 50-day avg
+4% above
◦
RSI (14)
57 · neutral
+
MACD trend
positive
◦
52-week position
46% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $6 › 200d $6 — 50d above 200d
+
Institutional flow
+33 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
1.98% of float · ▼ -16.0% MoM · 3.4 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
33 holders — 13F breadth
Fundamentals
Fair
−
Revenue growth
−4% Y/Y
+
Gross margin
43%, contracting
−
EPS growth
−357% Y/Y
+
Free cash flow
$5.5M
+
Valuation
P/E 0.7 · below peers
−
Balance sheet
net debt $27.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 12, 2026
Q2 2026
Revenue
Initiated
$20.5M – $22.5M
prior qtr $20.76M
midpoint +3.6% QoQ
Adjusted gross margin
Non-GAAP
Initiated
57% – 59%
Adjusted EBITDA
Non-GAAP
Initiated
$1M – $2M
Full Year 2026
Revenue growth
Initiated
2% – 4%
Adjusted gross margin
Non-GAAP
Initiated
58% – 60%
Adjusted EBITDA growth
Non-GAAP
Initiated
6% – 10%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+10% above
Bullish
Price vs 50-day avg
+4% above
Bullish
RSI (14)
57 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
46% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+33 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.98% of float · ▼ -16.0% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $4
Now $6 · 46%
52-wk high $9
vs 200-day avg +10%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $0.8M | first quarter of 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 59% | Q1 2026 call | — |
| Adjusted operating income non-GAAP | $0.2M | Q1 2026 call | — |
| Americas revenue growth | -9% | Q1 2026 call | — |
| Biopharma customer sales growth | 20% | Q1 2026 call | — |
| China revenue growth | 3% | Q1 2026 call | — |
| Europe revenue growth | 7% | Q1 2026 call | — |
| Recurring revenue mix (consumables and software as % of total revenues) | 55% | current | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HBIO
this stock
Harvard Bioscience Inc
|
$29.00M | -5.2% | -3.8% | 0.7 | 2.0% |
|
ISRG
Intuitive Surgical Inc
|
$153.29B | -23.6% | +20.5% | 52.6 | 2.2% |
|
MDLN
Medline Inc.
|
$56.50B | +2.4% | +11.5% | — | 2.1% |
|
BDX
Becton Dickinson & Co
|
$42.86B | +2.6% | +8.2% | 39.5 | 2.6% |
|
ALC
Alcon Inc
|
$33.32B | -13.3% | — | — | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HBIO | +5.1% | -2.0% | +0.8% | +3.3% | -5.2% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +2.1% | -1.2% | -7.5% | +2.7% | -15.4% |